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Background
The use of composite end points (CEP) in clinical trials and observational studies is widespread, despite continuing controversies on methodological and interpretational aspects. 1 It is commonly recommended to construct CEP only from component outcomes that represent different manifestations of similar pathophysiologic processes, are of similar patient importance, similar frequency, and with similar associations with the predictor/intervention. 2 In the cardiovascular field, where more than one third of trials use some kind of CEP, it has been shown that the effect estimates based on CEP are mostly driven by more frequent but less severe component outcomes. 3 Fatal component outcomes in clinical trials, on the other hand, tend to occur with the lowest frequency and often feature the weakest treatment effects. 4 The possibly complicating role of study duration and followup time has attracted hardly any attention in this context. It has been suggested, for example, that long-term studies on valve implantation need to consider time-related component outcomes, such as valve failure. 5 However, more generally, the contribution of fatal component outcomes may be expected to increase with substantial long-term follow-up, especially in chronic disease studies in the elderly. Fundamental to both examples-valve failure and higher age mortality-is the understanding that the relative composition of the CEP may change with increasing study duration. This could lead to study duration-dependent changes of the association of a risk factor with the CEP, not because of time-varying effects of the risk factor on the component outcomes, but because of a time-varying composition of the CEP.
Because the relevance of such study duration-dependent CEP compositions has not been investigated to date, the aim of the present work is to empirically address this issue in a cardiovascular patient cohort followed during 13 years.
Methods and Results
The present work is based on the observational KAROLA prospective cohort study (Langzeiterfolge der Kardiologischen Anschlussheilbehandlung [Longterm Success of Cardiological
Rehabilitation Therapy]) on prognosis of patients with chronic coronary heart disease. From January 1999 to May 2000, 1204 patients aged 30 to 70 years who were admitted to 1 of 2 participating rehabilitation clinics for inpatient rehabilitation within 3 months after an acute cardiovascular event (acute coronary syndrome or coronary artery bypass surgery) were recruited. Participation was voluntary and required written informed consent. The study complied with the declaration of Helsinki and had been approved by ethics boards of the physicians' chambers of Hessen and Baden-Württemberg, the University of Ulm, and the University of Heidelberg.
Details of the study design and procedures have been published elsewhere. 6, 7 In brief, data collection at baseline included self-administered standardized questionnaires on medical, sociodemographic, and health behavior variables and extraction of pertinent data from hospital records. Among other markers, free fatty acids (FFA) 8 and mid-regional proatrial natriuretic peptide (MR-proANP) 9 were measured in blood samples obtained at the end of the inpatient rehabilitation program. Participants were actively followed after 1, 3, 4.5, 6, 8, 10, and 13 years via standardized mailed questionnaire. Secondary cardiovascular events (nonfatal myocardial infarction or stroke) were ascertained by contacting the primary care physicians of the participants, likewise via standardized questionnaires at the same follow-up intervals. The main outcome of interest was time to a subsequent nonfatal cardiovascular event or circulatory death, analyzing only the first event. Alive subjects without a nonfatal event were censored at the last available follow-up, whereas deceased subjects contributed person-time until death and were censored if death was because of a noncirculatory cause. Finally, data for the present analysis was available for 1114 subjects, in whom, 280 main outcomes were observed during 13 years of follow-up.
The contribution of the nonfatal and fatal component outcomes to the CEP was first tabulated for increasing follow-up durations (Table) . The proportion of nonfatal events among the end points contributing to the CEP was initially high (70%) and monotonically decreased with longer follow-up duration, resulting in an almost even distribution toward the end of the study.
Subsequently, the association of various cardiovascular risk markers/ indicators at baseline (cineangio-or echocardiographically defined heart failure, levels of FFA, and levels of MR-proANP) with the occurrence of a secondary circulatory event (CEP, nonfatal, or fatal component outcomes) was analyzed in Cox proportional hazard models adjusted for important covariables (age, sex, number of affected vessels, creatinine clearance, and never versus former versus current smoking). Because the focus of the present work was on general patterns rather than a particular marker outcome relationship, this adjustment set was pragmatically chosen to remove substantial confounding in a parsimonious way. The markers were arbitrarily chosen to demonstrate a range of scenarios that can arise from changing CEP compositions with longer follow-up.
The associations of heart failure, FFA, and MR-proANP with the 3 different end points and the evolution of these associations over increasing study duration are shown in the Table. For all 3 markers (and for the majority of other markers not shown), the hazard ratios (HR) for the association with the fatal component outcome were stronger than those with the nonfatal component outcome. For heart failure, there were significant (P<0.05) associations with both component outcomes. The HR was decreasing with follow-up, especially for the fatal component, whereas the association with the CEP was essentially stable. For FFA, there was a rather stable and during later follow-up, clearly significant association only with the fatal component outcome. The HR for the nonfatal component outcome initially was elevated without significance and then essentially vanished with increasing follow-up, whereas the estimate for the CEP remained elevated throughout the study but reached statistical significance only intermittently. For MR-proANP, there was a slightly decreasing association with the fatal component outcome and a consistently elevated nonsignificant HR for the nonfatal outcomes. The association with the CEP was rather stable throughout the study.
Comment
Our tabulations expose the crucial importance that follow-up time can play in the context of analyzing CEP-an issue that by and large has been ignored in the literature. As generally known and demonstrated again in the above analyses, the association of a risk factor or marker with a CEP is a potentially complicated function of the associations of the pertinent variable with the component outcomes forming the CEP. 10 In particular, the associations with the component outcomes not only are often of varying extents but the contribution of the component outcomes to the CEP will often vary during follow-up. This situation, exemplified in our cohort study, most likely presents the norm rather than exception.
The issue demonstrated in this study may itself contribute to and be complicated by time-varying associations of baseline variables with the component outcomes or CEP. We have recently described how common changes of biomarker outcome associations during increasing long-term follow-up are and that they seem to be more frequent and pronounced than generally appreciated. 11 From this perspective, the association patterns of the 3 risk factors with the CEP could be summarized and explained as follows. For heart failure, the association with the CEP was essentially stable, resulting from a mixture of 2 component associations that were both weakening during follow-up and where the stronger one (with fatal outcomes) was increasing in relative importance with longer study duration. For FFA, the association with the CEP reached statistical significance only intermittently because the †Cox proportional hazards models adjusted for age, sex, renal function, number of affected vessels, and smoking, with n=969, n=1006, and n=1009 for heart failure, FFA, and MR-proANP, respectively, because of missing values. The proportional hazards assumption was tested for each predictor outcome combination by testing a predictor*log (observation time) interaction term; no significant deviation from proportional hazards was observed.
FFA indicates free fatty acid; and MR-proANP, mid-regional proatrial natriuretic peptide.
contribution of the fairly stable association with the fatal component outcome-clearly significant with increasing study duration-remained too low to reliably pull the overall association toward significance. For MR-proANP, the mixture of a stable nonsignificant risk increase and a significant, slightly decreasing association with the fatal component outcome lead to a stable association with the CEP, with slightly higher HR after longer follow-up than during the first years of the study.
Limitations of the present work include the possibility of residual confounding and limited statistical power to detect weaker associations. However, we adjusted for multiple major cardiovascular risk markers, which appeared parsimonious and adequate for the methodological purpose of the present work. The precision of our association estimates furthermore seemed sufficient to reveal distinct patterns between the different markers and component outcomes or CEP. Other analytic approaches, such as repeated or competing events models or parametric analyses, could not be addressed in this concise work. 12, 13 Changes in endpoint compositions also could affect measures of discrimination.
14 These issues could possibly best be investigated with well-defined simulations.
The present study did not aim to comprehensively discuss the potentials and pitfalls of CEP analysis, which have been excellently covered by others. 1, 10, [15] [16] [17] [18] [19] We note, however, that the practical relevance of the phenomenon described here will depend also on the study context. For instance, an etiologic study a priori might deem it most important to, for example, combine only outcomes featuring similar strength of association and underlying physiology, whereas a clinical trial might emphasize comparable patient importance, leading to different conclusions about which component or composite outcome and association is relevant and indeed worth contemplating. Comparability across studies may provide pragmatic motivation for CEP analyses and obviously could be compromised by different relative CEP compositions, for example, because of different age ranges. In any case, researchers studying CEP should generally consider additionally exploring the evolution of the CEP composition and of the component associations during increasing study duration, to elucidate how both factors together result in the association of a risk factor with the CEP as observed in the main analysis at the end of the study.
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